[
    [
        {
            "time": "",
            "original_text": "医保谈判第二日：医药股大涨 创新药竞逐",
            "features": {
                "keywords": [
                    "医保谈判",
                    "医药股",
                    "创新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医保谈判第二日：医药股大涨 创新药竞逐",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国家医保谈判“降价”依然是主旋律，感染药及PD(L)-1新适应症成角逐热点",
            "features": {
                "keywords": [
                    "国家医保",
                    "降价",
                    "感染药",
                    "PD(L)-1",
                    "适应症"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "国家医保谈判“降价”依然是主旋律，感染药及PD(L)-1新适应症成角逐热点",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国谈现场 | PD-1众星捧月，保密工作再升级",
            "features": {
                "keywords": [
                    "国谈",
                    "PD-1",
                    "保密工作"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国谈现场 | PD-1众星捧月，保密工作再升级",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "120万元一针抗癌神药首次进入医保谈判！能砍成多少？",
            "features": {
                "keywords": [
                    "抗癌神药",
                    "医保谈判",
                    "价格谈判"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "120万元一针抗癌神药首次进入医保谈判！能砍成多少？",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "【行情】医药板块持续走强，沃森生物涨超15%，恒瑞医药、司太立涨超9%，美诺华、君实生物、威尔药业、哈三联、贝达药业等涨幅居前",
            "features": {
                "keywords": [
                    "医药板块",
                    "沃森生物",
                    "恒瑞医药",
                    "君实生物"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【行情】医药板块持续走强，沃森生物涨超15%，恒瑞医药、司太立涨超9%，美诺华、君实生物、威尔药业、哈三联、贝达药业等涨幅居前",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 10,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]